Sign in Subscribe
Genetic research

Endometrial Cancer Study Reveals Aggressive Features and Treatment Implications

Strategic Insights

— 1 min read

A recent study at the Pomeranian Medical University in Poland has shed light on the characteristics and molecular features of endometrial cancer patients with TP53 gene mutations. The research, published in the Journal of Clinical Medicine, analyzed a cohort of 20 patients with histologically confirmed endometrial cancer and pathogenic TP53 mutations. The findings suggest that TP53-mutated endometrial cancers are associated with aggressive histopathological features and advanced staging.

Key Takeaways:

  • The study analyzed 20 patients with histologically confirmed endometrial cancer and pathogenic TP53 mutations treated at the Pomeranian Medical University Clinical Hospital No. 2 between January 2023 and March 2025.
  • Clinical, histological, and molecular data were collected, including FIGO stage, tumor grade, and coexisting mutations.
  • Patients had a mean age of 69.2 years and a mean BMI of 29.5 kg/m, with the most common histological types being endometrioid (45%) and serous carcinoma (40%).
  • Grade 3 tumors were found in 65% of cases, and 65% of patients exhibited lymphovascular space invasion.
  • 30% of patients were upstaged under the FIGO 2023 classification when incorporating TP53 mutation status.
  • Four patients had coexisting PIK3CA mutations.
  • Molecular profiling, particularly TP53 mutation assessment, provides essential prognostic information and may inform personalized therapeutic strategies.
  • Larger, multicenter studies are warranted to validate these findings and identify actionable molecular targets.

Statistics:

  • 69.2 years: mean age of patients in the study
  • 29.5 kg/m: mean BMI of patients in the study
  • 45%: proportion of patients with endometrioid tumors
  • 40%: proportion of patients with serous carcinoma
  • 65%: proportion of patients with grade 3 tumors
  • 65%: proportion of patients with lymphovascular space invasion
  • 30%: proportion of patients upstaged under the FIGO 2023 classification

Sources:

  • Clinicopathological Analysis of a Group of Patients Diagnosed with Endometrial Cancer and Mutation in the Tp53 Gene-Single-Center Study. Journal of Clinical Medicine, 2025;14(19):6809.
  • Journal of Clinical Medicine, Mdpi, St Alban-Anlage 66, Ch-4052 Basel, Switzerland.
  • Aleksandra Kukla-Jakubowska, Dept. of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, 70-111 Szczecin, Poland.
  • Dominik Jakubowski, Kaja Michalczyk, Marcin Misiek, Janusz Menkiszak, and Anita Chudecka-Glaz.

Read more